The findings suggest that the activation of the epidermal growth factor receptor (EGFR) contributes to YTHDF2 overexpression in glioblastoma, thereby linking EGFR signaling, a pivotal factor in the progression and resistance to therapy of glioma, to m6A-dependent mRNA modification [22]. The gene discussed is EGFR; the disease is central nervous system cancer.